down arrow

Crinetics Pharmaceuticals, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US22663K1079
USD
44.79
-5.17 (-10.35%)

Feb 05

NAS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

44.4848.00

52 Week

24.1057.50
Valuation
Technical
Day's Volume

CASH

1.04 M

Shareholding (Sep 2025)

FII

14.98%

Held by 127 FIIs

DII

22.81%

Held by 67 DIIs

Promoter

7.34%

How big is Crinetics Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Crinetics Pharmaceuticals, Inc. has a market capitalization of $2.89 billion, with net sales of $0.36 million and a net profit of -$328.25 million over the latest four quarters. The company reported shareholder's funds of $1.32 billion and total assets of $1.73 billion as of Dec 24.

Market Cap: As of Jun 18, Crinetics Pharmaceuticals, Inc. has a market capitalization of 2,890.03 million, classifying it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Crinetics Pharmaceuticals, Inc. reported net sales of 0.36 million and a net profit of -328.25 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1,324.81 million and total assets of 1,726.13 million.

View full answer

What does Crinetics Pharmaceuticals, Inc. do?

22-Jun-2025

Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on developing treatments for specialty endocrine diseases and related tumors. As of March 2025, it has a market cap of approximately $2.89 billion, with no net sales and a net loss of $97 million.

Overview: <BR>Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on the discovery and development of drugs to treat specialty endocrine diseases and endocrine-related tumors, operating within the Pharmaceuticals & Biotechnology industry and categorized as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -97 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 2,890.03 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.01 <BR>Return on Equity: -26.18% <BR>Price to Book: 2.30<BR><BR>Contact Details: <BR>Address: 10222 Barnes Canyon Rd Bldg 2, SAN DIEGO CA: 92121-2711 <BR>Tel: 1 858 4506464 <BR>Fax: 1 302 6365454 <BR>Website: https://www.crinetics.com/

View full answer

Who are in the management team of Crinetics Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, Crinetics Pharmaceuticals, Inc.'s management team includes Dr. R. Scott Struthers as CEO, along with several independent directors, including Dr. Wendall Wierenga as Chairman.

As of March 2022, the management team of Crinetics Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Dr. Wendall Wierenga, who serves as the Independent Chairman of the Board.<BR>- Dr. R. Scott Struthers, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Camille Bedrosian, who is an Independent Director.<BR>- Mr. Matthew Fust, who is also an Independent Director.<BR>- Dr. Stephen Kaldor, another Independent Director.<BR>- Mr. Weston Nichols, who serves as an Independent Director.<BR>- Ms. Stephanie Okey, who is an Independent Director.<BR><BR>In summary, the management team consists of a mix of independent directors and executive leadership, with Dr. R. Scott Struthers as the CEO.

View full answer

Is Crinetics Pharmaceuticals, Inc. overvalued or undervalued?

20-Sep-2025

As of August 7, 2025, Crinetics Pharmaceuticals, Inc. is considered risky and overvalued, with a Price to Book Value of 2.47, a negative EV to EBITDA of -4.88, and a year-to-date return of -30.61%, significantly underperforming compared to its peers and the S&P 500.

As of 7 August 2025, the valuation grade for Crinetics Pharmaceuticals, Inc. moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 2.47, an EV to EBITDA of -4.88, and a negative ROE of -26.18%. <BR><BR>In comparison to its peers, Crinetics shows a significantly lower EV to EBITDA ratio than PTC Therapeutics, Inc. at 3.1714 and Ultragenyx Pharmaceutical, Inc. at -7.2361, further highlighting its relative weakness in valuation. Additionally, while Crinetics has seen a 5.19% return over the past week, it has underperformed on a year-to-date basis with a -30.61% return compared to the S&P 500's 12.22%, reinforcing the notion that the stock may be overvalued in the current market environment.

View full answer

Is Crinetics Pharmaceuticals, Inc. technically bullish or bearish?

28-Oct-2025

As of October 24, 2025, Crinetics Pharmaceuticals, Inc. shows a mildly bullish trend with a bullish weekly MACD and moving averages, despite underperforming the S&P 500 year-to-date and over the past year, while significantly outperforming it over the last three years.

As of 24 October 2025, the technical trend for Crinetics Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bearish. The daily moving averages indicate a bullish stance. However, the monthly Bollinger Bands and KST show bearish signals, and the Dow Theory indicates a mildly bullish trend on the weekly timeframe with no trend on the monthly. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 year-to-date and over the past year, with returns of -19.83% and -30.22%, respectively, compared to the S&P 500's 15.47% and 16.90%. However, over the longer term, the stock has significantly outperformed the benchmark with a 3-year return of 141.26% versus 78.85% for the S&P 500. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD and moving averages.

View full answer

Compare Crinetics Pharmaceuticals, Inc. with Similar Stocks

IDEAYA Biosciences, Inc.Vericel Corp.PTC Therapeutics, Inc.
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

1

Poor long term growth as Operating profit has grown by an annual rate -234.52% of over the last 5 years

 
2

The company has declared negative results for the last 25 consecutive quarters

3

Risky - Negative EBITDA

4

Underperformed the market in the last 1 year

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 5,218 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.01

stock-summary
Return on Equity

-39.46%

stock-summary
Price to Book

4.87

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Sep 2025)
Net Profit:
-130 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
5.36%
0%
5.36%
6 Months
58.72%
0%
58.72%
1 Year
10.87%
0%
10.87%
2 Years
20.79%
0%
20.79%
3 Years
124.85%
0%
124.85%
4 Years
155.94%
0%
155.94%
5 Years
186.38%
0%
186.38%

Crinetics Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Crinetics Pharmaceuticals Hits Day Low of $38.81 Amid Price Pressure

Crinetics Pharmaceuticals Hits Day Low of $38.81 Amid Price Pressure

Crinetics Pharmaceuticals, Inc. has faced significant challenges, with a notable decline in stock performance and ongoing financial difficulties, including 25 consecutive quarters of negative results. Despite a substantial increase over the past three years, the company's recent trajectory and year-to-date performance raise concerns about its profitability and market position.

Read full news article

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
19.04%
EBIT Growth (5y)
-234.52%
EBIT to Interest (avg)
-198.84
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.01
Sales to Capital Employed (avg)
0.00
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.47
EV to EBIT
-4.84
EV to EBITDA
-4.88
EV to Capital Employed
-132.79
EV to Sales
1824.64
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-26.18%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 73 Schemes (54.87%)

Foreign Institutions

Held by 127 Foreign Institutions (14.98%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is -69.40% vs -33.57% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-141.60",
          "val2": "-87.00",
          "chgp": "-62.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-130.10",
          "val2": "-76.80",
          "chgp": "-69.40%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-997,104.90%",
          "val2": "0.00%",
          "chgp": "-99,710.49%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -75.00% vs -14.89% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -39.11% vs -30.87% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.00",
          "val2": "4.00",
          "chgp": "-75.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-336.10",
          "val2": "-221.50",
          "chgp": "-51.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-298.40",
          "val2": "-214.50",
          "chgp": "-39.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-326,134.70%",
          "val2": "-55,471.70%",
          "chgp": "-27,066.30%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoYstock-summary

Sep'25
Sep'24
Change(%)
Net Sales
0.10
0.00
Operating Profit (PBDIT) excl Other Income
-141.60
-87.00
-62.76%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-130.10
-76.80
-69.40%
Operating Profit Margin (Excl OI)
-997,104.90%
0.00%
-99,710.49%
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is -69.40% vs -33.57% in Sep 2024

All Quarterly Resultsstock-summary

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
1.00
4.00
-75.00%
Operating Profit (PBDIT) excl Other Income
-336.10
-221.50
-51.74%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-298.40
-214.50
-39.11%
Operating Profit Margin (Excl OI)
-326,134.70%
-55,471.70%
-27,066.30%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -75.00% vs -14.89% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -39.11% vs -30.87% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Crinetics Pharmaceuticals, Inc. stock-summary
stock-summary
Crinetics Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company is focused on the discovery and development of drugs to treat specialty endocrine diseases and endocrine-related tumors. It develops a pipeline of oral nonpeptide chemical entities that target peptide G protein coupled receptors (GPCRs) for the treatment of endocrine diseases. The Company’s lead product candidate is CRN00808 developed for the treatment of acromegaly. It also develops two other product candidates CRN02481 for hyperinsulinemia, and CRN01941 for the treatment of neuroendocrine tumors. CRN02481 and CRN01941 are both oral nonpeptide somastatin receptors that are in the pre-clinical stages of development. The company also conducts research programs on developing nonpeptide products for the treatment of Cushing’s disease.
Company Coordinates stock-summary
Company Details
10222 Barnes Canyon Rd Bldg 2 , SAN DIEGO CA : 92121-2711
stock-summary
Tel: 1 858 4506464
stock-summary
https://www.crinetics.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Download on App Store
Get it on Google Play
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."